OPR - Delayed Quote • USD CORT May 2024 32.000 call (CORT240517C00032000) Follow 0.2100 0.0000 (0.00%) As of April 22 at 10:14 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for CORT240517C00032000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CORT Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know Corcept (CORT) Completes Enrollment in Phase II ALS Study Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) Corcept (CORT) Completes Enrollment in Ovarian Cancer Study Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? Investing in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 114% gain Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
